Genetic Testing
Glioma Prognostic Panel Test
The Glioma Prognostic Panel Test helps assess the prognosis of glioma, a type of brain cancer, by analyzing key genetic markers like IDH1, IDH2, and MGMT. This test aids in treatment planning.
General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.
Review status: No completed medical review is recorded for this page.
At a glance
Plan your test
- Sample
- Formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 5% tumor tissue.
- Results
- Confirm with the laboratory before booking.
- Preparation
- No special patient preparation is required. Ensure the FFPE tissue block is properly labeled and shipped at room temperature.
Payment: M-Pesa and card options can be confirmed during booking.
Insurance & government schemes
Is this test covered for you?
We help you verify whether the Glioma Prognostic Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.
Providers & schemes we can help you check
Government & public schemes
Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.
Private insurers & employer schemes
Names shown for identification only — listing does not imply partnership or guarantee of coverage.
Have these ready when we check
- Insurer or scheme name & policy / member number
- A clinician's request / prescription for the test
- Pre-authorisation letter, if your plan requires one
Free coverage check
Ask us to verify your cover
Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.
Start with fit
Is this the right test for you?
The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.
- ✓Diagnosis of glioma
- ✓Assessment of glioma prognosis
- ✓Guidance for treatment planning
- ✓Identification of potential clinical trial eligibility
- ✓Patients experiencing symptoms suggestive of brain tumors (e.g., persistent headaches, seizures, neurological changes)
In plain language
What this test helps you understand
This test specifically looks for genetic mutations in the tumor tissue, focusing on important markers such as IDH1, IDH2, and MGMT. These markers provide valuable information about the tumor's behavior, its potential response to different therapies, and help oncologists make informed decisions about patient care.
This test is recommended for individuals who have been diagnosed with a glioma or are experiencing symptoms that may indicate a brain tumor, such as persistent headaches, seizures, changes in vision or speech, or unexplained neurological deficits. Patients with a family history of brain cancer might also benefit from this testing.
Medical review status
Clinical review pending
A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.
Meet the DNA Labs Kenya medical team →A simple process
What happens next?
You do not have to navigate the test alone. We help you move from question to next step.
Speak with us
We check the test and answer your questions before collection.
Give your sample
Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.
Understand your report
A counselor helps you understand the result and the next steps.
Choose your collection
Home collection or a lab visit
We will explain the sample, preparation, and next steps before anything is collected.
Home collection
Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.
Lab or hub visit
Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.
Ask about locations →Read your report
What common result terms mean
Questions people ask
Frequently asked questions
Collaboration
Open for partnership with hospitals, clinics, doctors & researchers
Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.
Hospitals & clinics
Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.
Doctors & specialists
LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.
Research institutions
Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.
Students & academic projects
Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.
Trust & transparency
Sources, standards & how this page is maintained
Standards & references
- ACMG/AMP technical standards for sequence variant interpretation
- ClinGen curation and gene–disease validity frameworks where applicable
- LOINC-coded reporting for interoperable results
- ISO 9001:2015 quality management; ISO 15189 accreditation in progress
Page provenance
- Last updated: September 27, 2026
- Medical review: not yet completed
- Written for patients & clinicians in Kenya; reviewed periodically against current guidance
Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.
Keep exploring
Related tests
Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test
The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.
Learn more →Bcell Rearrangement Detection Test
The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.
Learn more →Dpd Gene Mutations 5Fu Toxicity Detection Test
This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).
Learn more →Ganciclovir Resistance Detection Test
This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.
Learn more →